查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1578952

軟組織肉瘤市場：按治療類型、疾病類型、最終用戶、治療類型、分銷管道 - 全球預測 2025-2030

Soft Tissue Sarcomas Market by Treatment Type, Disease Type, End User, Therapy Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年軟組織肉瘤市場價值為67282萬美元，預計2024年將達到73082萬美元，複合年成長率為9.65%，到2030年將達到128282萬美元。

軟組織肉瘤 (STS) 代表出現在結締組織中的多種惡性，包括肌肉、脂肪、神經和血管。這些腫瘤罕見且多樣，需要準確的診斷和治療方法。隨著全球癌症發生率的不斷上升，對先進的 STS 治療技術和藥物的需求至關重要。該市場涵蓋全方位的診斷和治療性介入，從 MRI 和 CT 成像到標靶治療和手術方法。最終用途主要是醫院、癌症研究機構和專科診所。癌症發病率上升、診斷技術進步以及新藥和治療通訊協定的開發推動了市場成長。人工智慧與診斷的整合以及精準醫療的引入是未來有望成長的領域。生物技術創新，特別是基因組分析和免疫療法，具有巨大的潛力。然而，該市場面臨治療成本高、監管障礙和藥物核准複雜性等限制。另一個挑戰是低度開發地區的STS管理意識和專業知識較低。為了利用新的機遇，相關人員應專注於新型生物標記的研究和開發，利用人工智慧進行早期檢測，並擴大有前景的治療方法的臨床試驗。製藥公司和研究機構之間的合作可以加速個人化醫療的突破。創新還可以致力於改進手術技術並最大限度地減少放射治療和化療的副作用。儘管存在這些挑戰，STS 治療仍然受到大量關注和投資。整體而言，STS 市場的特點是技術創新格局快速發展，具有充足的夥伴關係機會、技術進步和策略研究方向，以推動改善患者治療結果和市場擴張。

主要市場統計
基準年[2023] 67282萬美元
預測年份 [2024] 73082萬美元
預測年份 [2030] 12,828.2 億美元
複合年成長率（%） 9.65%

市場動態：快速發展的軟組織肉瘤市場的關鍵市場洞察

軟組織肉瘤市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 軟組織肉瘤盛行率不斷增加，導致對有效治療的需求
    • 診斷工具的技術進步可提高早期檢測率和患者治療結果
    • 提高意識和政府努力促進軟組織肉瘤的早期診斷和早期治療
    • 對創新治療方法的研發活動進行大量投資
  • 市場限制因素
    • 軟組織肉瘤先進診斷工具的可用性有限且高成本
  • 市場機會
    • 擴大軟組織肉瘤治療的先進治療選擇
    • 加大軟組織肉瘤治療研發投入
    • 提高意識和早期診斷工作以改善軟組織肉瘤患者的預後
  • 市場挑戰
    • 由於軟組織肉瘤治療的分散性，全球範圍內的治療方法正在多樣化。

波特的五力：駕馭軟組織肉瘤市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更具彈性的市場定位。

PESTLE分析：了解軟組織肉瘤市場的外部影響

外部宏觀環境因素在塑造軟組織肉瘤市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解軟組織肉瘤市場的競爭格局

軟組織肉瘤市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣軟組織肉瘤市場供應商的績效評估

FPNV定位矩陣是評估軟組織肉瘤市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了軟組織肉瘤市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對軟組織肉瘤市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 軟組織肉瘤的流行增加了對有效治療方法的需求
      • 診斷工具的技術進步提高了早期檢測率和患者治療結果
      • 意識的提高和政府的努力促進了軟組織肉瘤的早期診斷和治療
      • 對創新治療方法的研發活動進行大量投資
    • 抑制因素
      • 軟組織肉瘤的先進診斷工具可用性有限且成本高昂
    • 機會
      • 擴大軟組織肉瘤治療的先進治療選擇
      • 加大軟組織肉瘤治療研發投入
      • 提高意識提升和早期診斷工作以改善軟組織肉瘤患者的預後
    • 任務
      • 軟組織肉瘤治療的片段化導致世界各地出現了多種治療選擇
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的軟組織肉瘤市場

  • 化療
  • 聯合治療
  • 免疫療法
  • 放射治療
  • 外科手術
  • 標靶治療

第7章軟組織肉瘤市場：依疾病類型

  • 血管肉瘤
  • 透明細胞肉瘤
  • 促纖維增生性小圓細胞瘤
  • 伊文氏肉瘤
  • 胃腸道基質腫瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
    • 去分化脂肪肉瘤
    • 混合性脂肪肉瘤
    • 黏液樣脂肪肉瘤
    • 多形性脂肪肉瘤
    • 高分化脂肪肉瘤
  • 惡性周邊神經鞘瘤
  • 橫紋肌肉瘤
    • 腺泡狀橫紋肌肉瘤
    • 未分化橫紋肌肉瘤
    • 胚胎性橫紋肌肉瘤
  • 滑膜肉瘤

第8章軟組織肉瘤市場：依最終使用者分類

  • 門診手術中心
  • 癌症治療與研究中心
  • 診所
  • 醫院
    • 私立醫院
    • 公立醫院

第9章按治療類型分類的軟組織肉瘤市場

  • 一線治療
  • 四線或更高級別的治療
  • 二線治療
  • 三線治療

第10章軟組織肉瘤市場：依通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲軟組織肉瘤市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太軟組織肉瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲軟組織肉瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-5D340F440B83

The Soft Tissue Sarcomas Market was valued at USD 672.82 million in 2023, expected to reach USD 730.82 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 1,282.82 million by 2030.

Soft Tissue Sarcomas (STS) represent a diverse group of malignant tumors that originate in the connective tissues, including muscles, fat, nerves, and blood vessels. These tumors are rare and diverse, demanding precise methods of diagnosis and treatment. With an increasing global burden of cancer, the need for advanced therapeutic techniques and pharmaceuticals for STS is critical. The market encompasses diagnostic and therapeutic interventions, involving everything from MRI and CT imaging to targeted therapies and surgical approaches. The end-use scope primarily spans hospitals, cancer research institutes, and specialized clinics. Market growth is driven by rising incidence rates of cancer, advancements in diagnostic technologies, and the development of novel drugs and treatment protocols. The integration of artificial intelligence with diagnostics and the adoption of precision medicine are promising areas for future growth. Biotech innovations, particularly in genomic analysis and immunotherapy, offer significant potential. However, the market faces limitations such as high treatment costs, regulatory hurdles, and the complexity in pharmaceutical approvals. Challenges also include limited awareness and expertise in STS management in underdeveloped regions. To leverage emerging opportunities, stakeholders should focus on research and development initiatives aimed at novel biomarkers, leveraging AI for early detection, and expanding clinical trials for promising therapeutic agents. Collaborations between pharmaceutical companies and research institutions can accelerate breakthroughs in personalized medicine. Innovation can also be directed towards improving surgical techniques and minimizing side effects of radiation and chemotherapy. Despite these challenges, STS therapies continue to attract significant attention and investment. Overall, the STS market is characterized by a burgeoning innovation landscape with ample opportunities for partnerships, technological advancements, and strategic research directions poised to improve patient outcomes and drive market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 672.82 million
Estimated Year [2024] USD 730.82 million
Forecast Year [2030] USD 1,282.82 million
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Soft Tissue Sarcomas Market

The Soft Tissue Sarcomas Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
    • Technological advancements in diagnostic tools improving early detection rates and patient outcomes
    • Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
    • Significant investments in research and development activities for innovative treatment options
  • Market Restraints
    • Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
  • Market Opportunities
    • Expansion of advanced therapeutic options for soft tissue sarcoma treatment
    • Increasing investment in research and development for soft tissue sarcoma therapies
    • Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
  • Market Challenges
    • Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Soft Tissue Sarcomas Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Soft Tissue Sarcomas Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Soft Tissue Sarcomas Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Soft Tissue Sarcomas Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Soft Tissue Sarcomas Market

A detailed market share analysis in the Soft Tissue Sarcomas Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Soft Tissue Sarcomas Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Soft Tissue Sarcomas Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Soft Tissue Sarcomas Market

A strategic analysis of the Soft Tissue Sarcomas Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Soft Tissue Sarcomas Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Soft Tissue Sarcomas Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chemotherapy, Combination Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on Disease Type, market is studied across Angiosarcoma, Clear Cell Sarcoma, Desmoplastic Small-Round-Cell Tumor, Ewing's Sarcoma, Gastrointestinal Stromal Tumors, Leiomyosarcoma, Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Rhabdomyosarcoma, and Synovial Sarcoma. The Liposarcoma is further studied across Dedifferentiated Liposarcoma, Mixed-Type Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, and Well-Differentiated Liposarcoma. The Rhabdomyosarcoma is further studied across Alveolar Rhabdomyosarcoma, Anaplastic Rhabdomyosarcoma, and Embryonal Rhabdomyosarcoma.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Cancer Treatment and Research Centers, Clinics, and Hospitals. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Therapy Type, market is studied across First-Line Therapy, Fourth-Line Therapy and Above, Second-Line Therapy, and Third-Line Therapy.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of soft tissue sarcomas leading to demand for effective treatments
      • 5.1.1.2. Technological advancements in diagnostic tools improving early detection rates and patient outcomes
      • 5.1.1.3. Rising awareness and government initiatives promoting early diagnosis and treatment of soft tissue sarcomas
      • 5.1.1.4. Significant investments in research and development activities for innovative treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability and high cost of advanced diagnostic tools for soft tissue sarcomas
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of advanced therapeutic options for soft tissue sarcoma treatment
      • 5.1.3.2. Increasing investment in research and development for soft tissue sarcoma therapies
      • 5.1.3.3. Rising awareness and early diagnosis initiatives to improve soft tissue sarcoma patient outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Fragmentation of soft tissue sarcoma treatment leading to varied management practices worldwide
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Soft Tissue Sarcomas Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combination Therapy
  • 6.4. Immunotherapy
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Soft Tissue Sarcomas Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Angiosarcoma
  • 7.3. Clear Cell Sarcoma
  • 7.4. Desmoplastic Small-Round-Cell Tumor
  • 7.5. Ewing's Sarcoma
  • 7.6. Gastrointestinal Stromal Tumors
  • 7.7. Leiomyosarcoma
  • 7.8. Liposarcoma
    • 7.8.1. Dedifferentiated Liposarcoma
    • 7.8.2. Mixed-Type Liposarcoma
    • 7.8.3. Myxoid Liposarcoma
    • 7.8.4. Pleomorphic Liposarcoma
    • 7.8.5. Well-Differentiated Liposarcoma
  • 7.9. Malignant Peripheral Nerve Sheath Tumors
  • 7.10. Rhabdomyosarcoma
    • 7.10.1. Alveolar Rhabdomyosarcoma
    • 7.10.2. Anaplastic Rhabdomyosarcoma
    • 7.10.3. Embryonal Rhabdomyosarcoma
  • 7.11. Synovial Sarcoma

8. Soft Tissue Sarcomas Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cancer Treatment and Research Centers
  • 8.4. Clinics
  • 8.5. Hospitals
    • 8.5.1. Private Hospitals
    • 8.5.2. Public Hospitals

9. Soft Tissue Sarcomas Market, by Therapy Type

  • 9.1. Introduction
  • 9.2. First-Line Therapy
  • 9.3. Fourth-Line Therapy and Above
  • 9.4. Second-Line Therapy
  • 9.5. Third-Line Therapy

10. Soft Tissue Sarcomas Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Soft Tissue Sarcomas Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Soft Tissue Sarcomas Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Soft Tissue Sarcomas Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Bayer AG
  • 5. Blueprint Medicines Corporation
  • 6. Boehringer Ingelheim
  • 7. Bristol-Myers Squibb
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eisai Co., Ltd.
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline plc
  • 12. Ipsen Biopharmaceuticals, Inc.
  • 13. Johnson & Johnson
  • 14. Kyowa Kirin Co., Ltd.
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Pfizer Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. SOFT TISSUE SARCOMAS MARKET RESEARCH PROCESS
  • FIGURE 2. SOFT TISSUE SARCOMAS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SOFT TISSUE SARCOMAS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SOFT TISSUE SARCOMAS MARKET DYNAMICS
  • TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLEAR CELL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DESMOPLASTIC SMALL-ROUND-CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EWING'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DEDIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MIXED-TYPE LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MYXOID LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PLEOMORPHIC LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY WELL-DIFFERENTIATED LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALVEOLAR RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANAPLASTIC RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY EMBRYONAL RHABDOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER TREATMENT AND RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FOURTH-LINE THERAPY AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY THIRD-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 230. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 238. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 246. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 254. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 262. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 270. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 278. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 286. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 291. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 292. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 294. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 299. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 300. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 302. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 307. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 308. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 310. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 315. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 316. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 318. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 324. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 326. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY RHABDOMYOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 334. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, 2018-2030 (USD MILLION)
  • TABLE 339. S